Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switching from Donepezil to Rivastigmine Patch in Alzheimer's Disease
NCT00428389Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2007
- Primary completion
- Feb 2008
- Modality
- Reversible Covalent Inhibitors, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of rivastigmine in Alzheimer's disease (AD), sponsored by Novartis. Started Jan 2007; status: completed.
02
Drugs
rivastigmine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00428389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00428389.